DWTX — Dogwood Therapeutics Share News
0.000.00%
Last trade - 00:00Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study
Dogwood Therapeutics Q1 net loss narrows, no revenue reported
Dogwood Therapeutics Q4 net loss narrows on lower expenses
Brief: Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Brief: Dogwood Therapeutics Reports Positive Interim Phase 2B Results In Chemotherapy-Induced Neuropathic Pain
Brief: Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC Filing
Dogwood Therapeutics' Q3 net loss widens on higher R&D costs
Brief: Dogwood Therapeutics Q3 EPS USD -8.2
Brief: Dogwood Therapeutics Inc - Secures Royalty-Free License For Sp16 In All-Stock Deal With Serpin Pharma
Dogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Dogwood Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview
Dogwood Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview
Brief: Dogwood Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Dogwood Therapeutics Inc expected to post a loss of $2.37 a share - Earnings Preview
Brief: Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance